Jing et al. reported that SIRT2 can block the degradation of the oncoprotein c-Myc, and the potent and specific SIRT2 inhibitor TM can effectively promote the ubiquitination and degradation of c-Myc, showing broad inhibitory effects against a variety of human cancers in vitro and in vivo. Here, SIRT2 is linked to cancer.